Erasca, Inc.

About Erasca, Inc.

Erasca is a clinical-stage precision oncology company with a mission to erase cancer by targeting one of cancer's most commonly mutated signaling cascades, the RAS/MAPK pathway. This pathway affects approximately 5.5 million lives worldwide each year. Erasca aims to transform cancer treatment and improve the lives of patients through a promising pipeline of therapies.

Products & Services

RAS/MAPK Pathway Therapies:A modality-agnostic portfolio of therapeutic programs designed to comprehensively shut down the RAS/MAPK pathway, a commonly mutated pathway in cancer affecting millions globally.

Specialties

Precision Oncology RAS/MAPK Pathway Targeting Cancer Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 258800000 MR: - FA: $258.8 million FAN: 258800000	D: 2026-01-23 FD: 2026-01-23	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 225000000 MR: - FA: $225.0 million FAN: 225000000	D: 2026-01-21 FD: 2026-01-21	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: 150.0 million FAN: 150000000	D: 2026-01-20 FD: 2026-01-20	4 investors
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 184000000 MR: - FA: approximately $184.0 million FAN: 184000000	D: 2024-05-21 FD: 2024-05-21	2 investors
5	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 160000000 MR: - FA: approximately $160 million FAN: 160000000	D: 2024-05-16 FD: 2024-05-16	2 investors
6	RT: Private Placement T: - FT: Private Placement	A: 45000000 MR: - FA: 45 million FAN: 45000000	D: 2024-03-27 FD: 2024-03-27	1 investors

Public Offering of Common Stock Latest

2026-01-23

$258.8M

4 investors (Pro only)

Public Offering 2026-01-21

$225.0M

Public Offering 2026-01-20

$150.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jonathan E. Lim

Chairman, CEO and Co-founder

M

Michael Varney

Chair of R&D, SAB Member and Board Director

D

David Chacko

Chief Financial Officer and Chief Business Officer

N

Nik Chetwyn

Chief Operating Officer

E

Ebun Garner

General Counsel

C

Chandra Lovejoy

Chief Regulatory Affairs Officer

View 25 more team members with Pro

Unlock Full Team Directory

Recent News

Erasca, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised